---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Economic information and modeling report. Covers Cost-effectiveness evidence. 36 evidence topics quoted from 26 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics/cost-effectiveness"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary: scope of the economic evidence

Envudeucitinib is an investigational drug. No cost-effectiveness, cost per responder, or budget impact analysis that includes envudeucitinib was found, and the report records no price for it. The evidence under this heading covers comparator prices from state, federal, and manufacturer sources; the 2016 and 2018 ICER assessments of targeted immunomodulators for plaque psoriasis; published cost-effectiveness, cost per responder, and budget impact analyses of comparators; and market statements by Alumis.

Source: [Alumis envudeucitinib for psoriasis page](https://www.alumis.com/pipeline/envudeucitinib-for-psoriasis/); [ICER targeted immunomodulators for plaque psoriasis final evidence report (2016)](https://icer.org/wp-content/uploads/2020/10/NE_CEPAC_Psoriasis_Evidence_Report_FINAL_012317.pdf); [ICER targeted immunomodulators for plaque psoriasis final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_Psoriasis_Update_Final_Evidence_Report_10042018.pdf)

<a id="topic-4.1-2"></a>

#### Summary: comparator prices by source

Prices are given as each source lists them, in U.S. dollars.

- Texas DSHS 2026 annual WAC report: Sotyktu 7135.55; TREMFYA 14566.44; TALTZ 7624.59; BIMZELX 160MG/ML auto-injector pen 8350.73; STELARA 29151.48 and 29151.46 (two NDCs); Otulfi 45 MG/0.5ML 1809.79; SELARSDI 45MG/0.5ML 2088.21; HUMIRA PEN 6922.62.
- California HCAI WAC increase file, January to October 2026: Otezla 30mg 60 pack and Otezla 75 mg extended-release 30 pack 5589.89 each (effective 01/07/2026); SKYRIZI PEN 150 mg 23838.42 (01/02/2026); COSENTYX 150 mg pen 8165.42 and 300 mg pen 8492.03 (01/07/2026); Enbrel Sureclick 50mg 4 pack 8565.48 (01/07/2026); SILIQ 210mg box of 2 syringes 6928.92 (05/11/2026); Cimzia 2 x 200 mg kit 6299.40 (01/01/2026).
- California HCAI new prescription drugs file: ICOTYDE 200mg tablet, package size 30, WAC at introduction 8285.0000 on 2026-03-18, with an estimated patient count of 8000000 in the filing.
- Department of Veterans Affairs Federal Supply Schedule, from 01/01/2026 unless noted: SOTYKTU 6MG TAB (30) FSS 6088.27 and Big Four 4815.81; OTEZLA 30MG TAB (60) 3495.82; OTEZLA XR 75MG TAB (30) 4775.29 from 01/29/2026; TREMFYA 100MG/ML 13931.32; SKYRIZI 150MG/ML 15522.22; STELARA 45MG/0.5ML 13980.15; ILUMYA 100MG/ML 11842.56; COSENTYX PEN (2 PENS) 6835.37; ENBREL 50MG/ML SURECLICK (4) 6933.40; HUMIRA 40MG/0.4ML (2) 5879.01.
- CMS Medicare Part B payment limits effective October 1, 2026 through December 31, 2026, based on 2Q26 ASP data, per 1 mg: tildrakizumab 120.965, guselkumab 66.998, risankizumab 14.011, intravenous secukinumab 18.131, intravenous ustekinumab 10.249, and certolizumab pegol 3.140; infliximab 29.856 per 10 mg.
- Medicare negotiation: the negotiated price for Otezla and Otezla XR (Amgen Inc.) is $1,650 for a 30-day supply in CY 2027, a 65% discount from the CY 2024 list price of $4,722; 31,000 Medicare Part D enrollees used the drug in CY 2024, with $1,045,443,000 in total Part D gross covered prescription drug costs. Cosentyx and Cimzia were selected for the third cycle of negotiation, with any negotiated prices effective beginning in 2028.
- Bristol Myers Squibb offers Sotyktu to eligible cash-pay U.S. patients through BMS Patient Connect, beginning January 2026, at more than 80% less than the current list price.

Source: [Texas DSHS 2026 annual WAC report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2026-annual-wac-report_1026.xlsx); [California HCAI prescription drug WAC increases, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/dda8a083-bc81-4f6d-b02f-935a2df70328/download/wac-increase-data-jan-oct-2026.csv); [California HCAI new prescription drugs introduced to market, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv); [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://www.va.gov/opal/docs/nac/fss/vaFssPharmPrices.xlsx); [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip); [CMS negotiated prices fact sheet (2025)](https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf); [CMS fact sheet, third cycle of negotiation (2026)](https://www.cms.gov/files/document/fact-sheet-medicare-drug-price-negotiation-third-cycle.pdf); [Bristol Myers Squibb press release, BMS Patient Connect platform (2025)](https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Builds-on-Eliquis-apixaban-Direct-to-Patient-Program-Announces-New-BMS-Patient-Connect-Platform-Offering-Sotyktu-deucravacitinib/default.aspx)

<a id="topic-4.1-3"></a>

#### Summary: ICER assessments of targeted immunomodulators

- 2016 report: cost per QALY versus non-targeted therapy was $89,610 for apremilast, $89,843 for secukinumab, $92,715 for infliximab, $94,030 for brodalumab, $100,389 for ixekizumab, $108,040 for adalimumab, $117,769 for etanercept, and $129,904 for ustekinumab; results for brodalumab were tentative because pricing was not available. Using WAC prices, the ratios ranged from $140,000 to $187,000 per QALY gained. All drugs except adalimumab, apremilast, and infliximab required discounts from WAC to fall within the threshold range of $100,000 to $150,000/QALY. The candidate population, adults with moderate-to-severe plaque psoriasis taking a biologic agent for the first time, was approximately 36,750 incident cases per year; against a threshold of $904 million per year for 2015-16, the potential budgetary impact averaged approximately $239.8 million per year for brodalumab and approximately $266 million per year for ixekizumab.
- 2018 report: net prices for all drugs except infliximab were derived from SSR Health, LLC. The cost-effectiveness table gives cost per QALY versus non-targeted treatment from $131,000 for brodalumab to $188,000 for certolizumab pegol, with $135,000 for apremilast; the text gives the base-case range as $133-$188K/QALY and states that including productivity offsets lowered the ratios to $109-166K/QALY. At a $50K/QALY threshold no targeted drugs offered good value, and at a $100,000 per QALY threshold, initiation with brodalumab or infliximab each had a 10% probability of being optimal value. Annual discounts required to reach $100,000 per QALY ranged from 38% to 71%, and to reach $150,000 per QALY from 8% to 44%; for apremilast, the annual WAC was $40,000, the estimated net price $31,000, and the price to achieve $100,000 per QALY $17,500. The report states that IL-17 drug prices had increased since the 2016 report.
- 2018 budget impact: 29,342 incident cases of moderate-severe plaque psoriasis per year (approximately 146,710 over five years); at all prices except the price to reach $50,000 per QALY, the annual potential budgetary impact exceeded the threshold of $915 million, with an additional per-patient cost of approximately $58,900 at WAC and approximately $37,200 with the assumed discount.

Source: [ICER targeted immunomodulators for plaque psoriasis final evidence report (2016)](https://icer.org/wp-content/uploads/2020/10/NE_CEPAC_Psoriasis_Evidence_Report_FINAL_012317.pdf); [ICER targeted immunomodulators for plaque psoriasis final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_Psoriasis_Update_Final_Evidence_Report_10042018.pdf)

<a id="topic-4.1-4"></a>

#### Summary: cost-effectiveness and cost per responder analyses of comparators

- Hendrix et al.: in a 10-year Markov model with WAC discounted by a class-specific rebate percentage off 2016 costs, costs of care without targeted treatment totaled $66,451 and costs of targeted treatment ranged from $137,080 (apremilast) to $255,422 (ustekinumab); infliximab and apremilast were likely to be the most cost-effective initial treatments at thresholds around $100,000 per QALY, and IL-17 drugs at thresholds approaching $150,000 per QALY.
- Jia et al.: over 10 years, the incremental cost per QALY gained was lowest for brodalumab, infliximab, apremilast, and tildrakizumab.
- Kong and Buzney: mean annual total costs were $84,034 for biologics, $14,760 for office phototherapy, and $6222 for home phototherapy, with mean QALY gains of 0.24 for biologics, 0.18 for phototherapy, and 0.23 for step therapy.
- Egilman et al.: U.S. net prices of 13 biologic therapies ranged from $1664 to $79,277 per year, with a median net annual treatment cost of $34,965; U.S. prices would need a median reduction of 71% to align with efficiency frontier estimates.
- Park et al.: the cost per response of deucravacitinib versus apremilast was lower at 16 weeks (difference -$3796) and 24 weeks (difference -$12,784), and at 52 weeks the cost per cumulative benefit was lower for patients who initiated deucravacitinib.
- Wu et al. (cost per month with a PASI 75 response): the incremental cost per extra month with a PASI 75 response ranged from $3,685 for brodalumab to $13,476 for certolizumab pegol, with $4,770 for apremilast. Wu et al. (annual cost per response): the annual cost per PASI 75 was $48,782 for brodalumab and $87,243 for ustekinumab.
- Teeple and Muser and Teeple and Fitzgerald: the cost per PASI 90 response was $113,861 for guselkumab against $151,226 for adalimumab in the induction year, and $89,960 for guselkumab against $110,977 for secukinumab at 48 weeks.
- Blauvelt et al.: over 16 weeks, guselkumab had the lowest cost per cumulative benefit for PASI 90 ($99,742) and ixekizumab for PASI 100 ($230,884).
- McCoy et al.: NB-UVB had an adjusted monthly cost of $1714.00 per PASI 75, and infliximab, the least expensive biologic, $2076.00 to $2502.00.

Source: [Hendrix et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10398188/); [Jia et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/32602762/); [Kong and Buzney (2026)](https://pubmed.ncbi.nlm.nih.gov/41739454/); [Egilman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10882509/); [Park et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38914425/); [Wu et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32233828/); [Wu et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29658383/); [Teeple and Muser (2019)](https://pubmed.ncbi.nlm.nih.gov/31199173/); [Teeple and Fitzgerald (2022)](https://pubmed.ncbi.nlm.nih.gov/32479140/); [Blauvelt et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391184/); [McCoy et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37066447/)

<a id="topic-4.1-5"></a>

#### Summary: published budget impact analyses of comparators

- Carrico et al.: a health plan of 1,000,000 members, with psoriasis prevalence of 3.2%, 90.0% with plaque psoriasis, 18.2% with moderate-to-severe disease, 20.0% treated with a biologic or apremilast, and 35.6% new users, had an estimated 1048 patients receiving biologics or apremilast. Adding tildrakizumab reduced total annual health plan cost by $5585 in year 1 and $342,563 in year 5, a cumulative $964,763 over 5 years, with per member per month reductions of $0.03 or less. Acquisition costs were based on WACs from May 2019.
- Feldman et al.: in a hypothetical commercial health plan of two million members, 7,038 moderate-to-severe psoriasis patients were estimated to be eligible for brodalumab; the total annual pharmacy budget for biologics without brodalumab was $414,362,647, and brodalumab use of 3%, 8%, 16%, and 30% reduced it by $3,698,129, $9,861,677, $19,723,355, and $36,981,290.

Source: [Carrico et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7688845/); [Feldman et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29357713/)

<a id="topic-4.1-6"></a>

#### Summary: market statements by Alumis

In its corporate presentation, Alumis describes psoriasis as a “Large marketplace with modest treatment penetration”, states that historical market share trends show a multi-winner market and that the uptake of Icotyde is largely additive, and reports that 84% of patients and 73% of dermatologists believe there is a need for better psoriasis therapies. In its annual report, Alumis states that the precise incidence and prevalence for the conditions it aims to address are unknown, that its estimates derive from sources including sales of competitors and market research and may prove to be incorrect, and that pricing of competitive products may limit the amount it will be able to charge for its product candidates, if approved.

Source: [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4); [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-4.1-7"></a>

#### Wholesale acquisition cost of deucravacitinib in the Texas 2026 annual report

| Field | Quoted value |
| --- | --- |
| Manufacturer | “Bristol-Myers Squibb Company” |
| Drug trade name | “Sotyktu” |
| Drug generic name | “deucravacitinib” |
| NDC11 | “3089511” |
| WAC price | “7135.55” |

Source: [Texas DSHS 2026 annual WAC report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2026-annual-wac-report_1026.xlsx)

<a id="topic-4.1-8"></a>

#### Cash-pay offer for deucravacitinib through BMS Patient Connect beginning January 2026

> “Beginning January 2026, Sotyktu, BMS’ medicine for moderate-to-severe plaque psoriasis, will be offered through the new BMS Patient Connect platform, which follows the launch of our Bristol Myers Squibb-Pfizer Alliance program for Eliquis® (apixaban) earlier this month.”
> “The platform will offer Sotyktu at more than 80% less than the current list price.”
> “Eligible cash-pay U.S. patients with a Sotyktu prescription will be able to purchase the medicine via BMS Patient Connect with access to shipping across all 50 states and Puerto Rico and with full transparency into the costs of their medicines – providing a direct, simplified access option.”

Source: [Bristol Myers Squibb press release, BMS Patient Connect platform (2025)](https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Builds-on-Eliquis-apixaban-Direct-to-Patient-Program-Announces-New-BMS-Patient-Connect-Platform-Offering-Sotyktu-deucravacitinib/default.aspx)

<a id="topic-4.1-9"></a>

#### Wholesale acquisition cost of icotrokinra at introduction in March 2026

| Field | Quoted value |
| --- | --- |
| Manufacturer | “Janssen Biotech, Inc.” |
| NDC | “57894020130” |
| Product description | “Strength: 200mg” |
| Product description, form and package | “Form: Tablet Package Size: 30” |
| Date introduced to market | “2026-03-18” |
| WAC at introduction | “8285.0000” |
| Estimated patients | “8000000” |

Source: [California HCAI new prescription drugs introduced to market, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv)

> “The pricing plan has WAC package price set for 200mg tablet at $8,285.”
> “The list price of ICOTYDE will also be discounted as required under the 340B program, Federal Supply Schedule, and other government programs.”

Source: [California HCAI new prescription drugs introduced to market, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv)

<a id="topic-4.1-10"></a>

#### Eligible population stated by the manufacturer of icotrokinra in its California filing

> “Over 8 million people in the US are living with psoriasis.”
> “ICOTYDE is indicated for patients with moderate to severe plaque psoriasis.”
> “Exact information for the ICOTYDE indicated population is not available in the public domain.”

Source: [California HCAI new prescription drugs introduced to market, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv)

<a id="topic-4.1-11"></a>

#### Wholesale acquisition costs of apremilast and injectable biologics after 2026 increases

| Product | Drug product description | WAC effective date | WAC after increase |
| --- | --- | --- | --- |
| OTEZLA 30 mg | “Otezla, 30mg, Tablet, 60 pack” | “01/07/2026” | “5589.89” |
| OTEZLA XR 75 mg | “Otezla, 75 mg Tablet, Extended Release 25 HR, 30 pack” | “01/07/2026” | “5589.89” |
| SKYRIZI 150 mg pen | “SKYRIZI PEN PEN INJECTOR (ML) 150 mg/mL 1” | “01/02/2026” | “23838.42” |
| COSENTYX 150 mg pen | “COSENTYX PEN INJECTION SYRINGE 150 mg/mL 1” | “01/07/2026” | “8165.42” |
| COSENTYX 300 mg pen | “COSENTYX UNOREADY PEN INJECTION SYRINGE 300 mg/2 mL (150 mg/mL) 1” | “01/07/2026” | “8492.03” |
| ENBREL 50 mg autoinjector | “Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pack” | “01/07/2026” | “8565.48” |
| SILIQ 210 mg | “SILIQ™ (brodalumab) Injection 210mg/1.5mL (1 box of 2 syringes)” | “05/11/2026” | “6928.92” |
| CIMZIA 200 mg | “Cimzia prefilled syringe kit, 2 x 200 mg/ml prefilled syringes” | “01/01/2026” | “6299.40” |

Source: [California HCAI prescription drug WAC increases, January to October 2026 (2026)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/dda8a083-bc81-4f6d-b02f-935a2df70328/download/wac-increase-data-jan-oct-2026.csv)

<a id="topic-4.1-12"></a>

#### Wholesale acquisition costs of injectable biologics and ustekinumab biosimilars in the Texas 2026 annual report

| Product | Drug trade name | NDC11 | WAC price |
| --- | --- | --- | --- |
| Guselkumab | “TREMFYA” | “57894064001” | “14566.44” |
| Ixekizumab | “TALTZ” | “2890511” | “7624.59” |
| Bimekizumab 160 mg | “BIMZELX 1 x 160MG/ML AUTO-INJECTOR PEN” | “50474078184” | “8350.73” |
| Ustekinumab | “STELARA” | “57894006003” | “29151.48” |
| Ustekinumab | “STELARA” | “57894006103” | “29151.46” |
| Ustekinumab-aauz 45 mg | “Otulfi Subcutaneous Solution Prefilled Syringe 45 MG/0.5ML” | “65219082401” | “1809.79” |
| Ustekinumab-aekn 45 mg | “SELARSDI PREFILLED SYRINGE 45MG/0.5ML 1” | “51759050532” | “2088.21” |
| Adalimumab | “HUMIRA PEN” | “74433902” | “6922.62” |

Source: [Texas DSHS 2026 annual WAC report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2026-annual-wac-report_1026.xlsx)

<a id="topic-4.1-13"></a>

#### Federal Supply Schedule and Big Four prices for oral and injectable comparators

| Product | Trade name | Package description | Price type | Price | Price start date | Price stop date |
| --- | --- | --- | --- | --- | --- | --- |
| Deucravacitinib 6 mg | “SOTYKTU 6MG TAB” | “30” | FSS | “6088.27” | “01/01/2026” | “04/30/2029” |
| Deucravacitinib 6 mg | “SOTYKTU 6MG TAB” | “30” | Big Four | “4815.81” | “01/01/2026” | “04/30/2029” |
| Apremilast 30 mg | “OTEZLA 30MG TAB” | “60” | FSS and Big Four | “3495.82” | “01/01/2026” | “07/31/2026” |
| Apremilast 75 mg extended release | “OTEZLA XR 75MG TAB” | “30” | FSS | “4775.29” | “01/29/2026” | “07/31/2026” |
| Guselkumab 100 mg | “TREMFYA 100MG/ML INJ” | “1ML” | FSS | “13931.32” | “01/01/2026” | “08/31/2029” |
| Risankizumab 150 mg | “SKYRIZI 150MG/ML INJ,SYRINGE,KIT” | “1ML” | FSS | “15522.22” | “01/01/2026” | “07/31/2030” |
| Ustekinumab 45 mg | “STELARA 45MG/0.5ML PFS (ULTRA-SAFE)” | “1X45MG/0.5ML” | FSS | “13980.15” | “01/01/2026” | “08/31/2029” |
| Tildrakizumab 100 mg | “ILUMYA 100MG/ML INJ,SYRINGE,1ML” | “1ML” | FSS | “11842.56” | “01/01/2026” | “07/14/2026” |
| Secukinumab 150 mg | “COSENTYX PEN (2 PENS)” | “2X1ML” | FSS | “6835.37” | “01/01/2026” | “08/31/2026” |
| Etanercept 50 mg | “ENBREL 50MG/ML SURECLICK AUTOINJECTOR” | “4” | FSS | “6933.40” | “01/01/2026” | “07/31/2026” |
| Adalimumab 40 mg | “HUMIRA 40MG/0.4ML INJ,SYRINGE,PEN” | “2” | FSS | “5879.01” | “01/01/2026” | “07/31/2030” |

Source: [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://www.va.gov/opal/docs/nac/fss/vaFssPharmPrices.xlsx)

<a id="topic-4.1-14"></a>

#### Medicare Part B payment limits for physician-administered biologics, fourth quarter of 2026

> “Effective October 1, 2026 through December 31, 2026”
> “Note 1: Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data.”

Source: [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

| Product | HCPCS code | Short description | HCPCS code dosage | Payment limit |
| --- | --- | --- | --- | --- |
| Tildrakizumab | “J3245” | “Inj., tildrakizumab, 1 mg” | “1 MG” | “120.965” |
| Guselkumab | “J1628” | “Inj., guselkumab, 1 mg” | “1 MG” | “66.998” |
| Risankizumab | “J2327” | “Inj risankizumab-rzaa 1 mg” | “1 MG” | “14.011” |
| Certolizumab pegol | “J0717” | “Certolizumab pegol inj 1mg” | “1 MG” | “3.140” |
| Infliximab | “J1745” | “Infliximab not biosimil 10mg” | “10 MG” | “29.856” |
| Ustekinumab, intravenous | “J3358” | “Ustekinumab, iv inject, 1 mg” | “1 MG” | “10.249” |
| Secukinumab, intravenous | “J3247” | “Inj secukinumab intrav 1mg” | “1 MG” | “18.131” |

Source: [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

<a id="topic-4.1-15"></a>

#### Medicare negotiated price for apremilast effective January 2027

> “Below is the list of negotiated prices, which the statute refers to as maximum fair prices (MFPs), for the 15 selected drugs covered under Medicare Part D that will go into effect beginning January 1, 2027, based on negotiations and agreements reached between CMS and participating drug companies.”

Source: [CMS negotiated prices fact sheet (2025)](https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf)

| Field | Quoted value |
| --- | --- |
| Drug name | “Otezla; Otezla XR” |
| Participating drug company | “Amgen Inc.” |
| Agreed to negotiated price for 30-day supply for CY 2027 | “$1,650” |
| List price for 30-day supply, CY 2024 | “$4,722” |
| Discount of negotiated price from 2024 list price | “65%” |
| Total Part D gross covered prescription drug costs, CY 2024 | “$1,045,443,000” |
| Number of Medicare Part D enrollees who used the drug, CY 2024 | “31,000” |

Source: [CMS negotiated prices fact sheet (2025)](https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf)

<a id="topic-4.1-16"></a>

#### Selection of secukinumab and certolizumab pegol for the third cycle of Medicare negotiation

> “On January 27, 2026, CMS announced the 15 drugs payable under Medicare Part B and/or covered under Medicare Part D selected for the third cycle of negotiations.”
> “Any negotiated prices will be effective beginning in 2028.”

Source: [CMS fact sheet, third cycle of negotiation (2026)](https://www.cms.gov/files/document/fact-sheet-medicare-drug-price-negotiation-third-cycle.pdf)

| Drug name | Participating manufacturer |
| --- | --- |
| “Cimzia” | “UCB, Inc.” |
| “Cosentyx” | “Novartis Pharmaceuticals Corporation” |

Source: [CMS fact sheet, third cycle of negotiation (2026)](https://www.cms.gov/files/document/fact-sheet-medicare-drug-price-negotiation-third-cycle.pdf)

<a id="topic-4.1-17"></a>

#### Drug cost inputs and estimated net prices in the 2018 ICER assessment

> “With the exception of infliximab, net pricing estimates for all reviewed drugs were derived from SSR Health, LLC, which combines data on unit sales with publicly-disclosed US sales figures that are net of discounts, rebates, concessions to wholesalers and distributors, and patient assistance programs to derive a net price.”

Source: [ICER targeted immunomodulators for plaque psoriasis final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_Psoriasis_Update_Final_Evidence_Report_10042018.pdf)

| Intervention | Unit | WAC per unit or dose | Discount | Net price per unit | Cost of first year | Annual cost of year 2 and later |
| --- | --- | --- | --- | --- | --- | --- |
| Adalimumab | “40 mg” | “$2,436.02” | “31%” | “$1,674.64” | “$46,751.16” | “$43,693.75” |
| Apremilast | “30 mg” | “$54.72” | “22%” | “$42.46” | “$30,807.28” | “$31,019.58” |
| Brodalumab | “210 mg” | “$1,750.00” | “20%” | “$1,400.00” | “$37,684.00” | “$36,528.00” |
| Certolizumab pegol | “400 mg” | “$4,044.32” | “36%” | “$2,583.70” | “$54,097.14” | “$50,559.32” |
| Etanercept | “50 mg” | “$1,218.00” | “31%” | “$837.69” | “$54,641.32” | “$43,713.06” |
| Guselkumab | “100 mg” | “$10,158.52” | “33%” | “$6,806.21” | “$50,609.02” | “$44,395.93” |
| Infliximab | “450 mg” | “$1,167.82” | “22%” | “$911.99” | “$38,466.44” | “$29,743.90” |
| Ixekizumab | “80 mg” | “$5,161.60” | “44%” | “$2,888.74” | “$51,374.18” | “$37,685.68” |
| Secukinumab | “300 mg” | “$4,712.38” | “38%” | “$2,926.22” | “$49,624.51” | “$38,174.63” |

Source: [ICER targeted immunomodulators for plaque psoriasis final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_Psoriasis_Update_Final_Evidence_Report_10042018.pdf)

<a id="topic-4.1-18"></a>

#### Costs, QALYs, and cost per QALY of first-line targeted therapies in the 2018 ICER assessment

| First-line treatment | Total cost | Total QALYs | Cost per QALY versus non-targeted treatment | Cost per month in PASI 75 or better |
| --- | --- | --- | --- | --- |
| Non-targeted treatment | “$67,800” | “5.70” | Not applicable | Not applicable |
| Adalimumab | “$308,000” | “7.17” | “$164,000” | “$3,200” |
| Apremilast | “$215,000” | “6.79” | “$135,000” | “$2,800” |
| Brodalumab | “$289,000” | “7.39” | “$131,000” | “$2,600” |
| Certolizumab pegol | “$341,000” | “7.16” | “$188,000” | “$3,700” |
| Etanercept | “$272,000” | “6.88” | “$175,000” | “$3,500” |
| Guselkumab | “$342,000” | “7.40” | “$161,000” | “$3,200” |
| Infliximab | “$238,000” | “6.98” | “$134,000” | “$2,700” |
| Ixekizumab | “$311,000” | “7.42” | “$142,000” | “$2,800” |
| Secukinumab | “$305,000” | “7.34” | “$145,000” | “$2,900” |
| Ustekinumab | “$315,000” | “7.17” | “$169,000” | “$3,300” |

Source: [ICER targeted immunomodulators for plaque psoriasis final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_Psoriasis_Update_Final_Evidence_Report_10042018.pdf)

> “In the base-case, ixekizumab has an ICER of $142,000 per QALY compared to non-targeted, and an ICER of $72,000 per QALY compared to etanercept.”
> “These results indicate that at a $50K/QALY threshold, no targeted drugs offer good value; at a $100K/QALY threshold, initiation with brodalumab or infliximab each have a 10% probability of being optimal value, and probabilities for the other targeted agents are all near zero; and at a $150K/QALY threshold there is more separation, as initiation with brodalumab or infliximab is most likely to be cost effective, while the other IL-17s and guselkumab have somewhat lower probabilities of being most cost effective.”
> “Including productivity offsets led to 10-13% decreases in total costs, and ICER’s compared to non-targeted that were notably lower than in the base case (i.e., $109-166K/QALY rather than $133-$188K/QALY).”
> “Our analysis indicates first-line treatment with infliximab or the IL-17 drugs is cost effective at higher willingness to pay thresholds, and infliximab and brodalumab are most likely to be cost effective.”
> “Guselkumab may be cost effective depending on drug discounts, and apremilast, while the least effective drug, may be cost effective at moderate willingness to pay thresholds.”
> “Among the IL-17’s, initiation with brodalumab appears to be the most cost-effective strategy due to drug pricing.”
> “Of note, the IL-17 drug prices have increased, leading to less favorable value than in our 2016 report.”

Source: [ICER targeted immunomodulators for plaque psoriasis final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_Psoriasis_Update_Final_Evidence_Report_10042018.pdf)

<a id="topic-4.1-19"></a>

#### Value-based price benchmarks in the 2018 ICER assessment

> “Annual prices and discounts required to reach the $100,000 per QALY threshold ranged from 38% to 71% and to reach the $150,000 per QALY threshold ranged from 8% to 44%.”

Source: [ICER targeted immunomodulators for plaque psoriasis final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_Psoriasis_Update_Final_Evidence_Report_10042018.pdf)

| Drug | Annual WAC | Annual estimated net price | Annual price to achieve $100,000 per QALY | Annual price to achieve $150,000 per QALY | Discount from WAC required to reach threshold prices |
| --- | --- | --- | --- | --- | --- |
| Adalimumab | “$63,600” | “$43,700” | “$25,700” | “$39,800” | “37% to 60%” |
| Apremilast | “$40,000” | “$31,000” | “$17,500” | “$36,600” | “8% to 56%” |
| Brodalumab | “$45,700” | “$36,500” | “$28,200” | “$41,500” | “9% to 38%” |
| Certolizumab pegol | “$79,100” | “$50,600” | “$25,500” | “$39,700” | “43% to 63%” |
| Etanercept | “$63,600” | “$43,700” | “$18,500” | “$35,400” | “44% to 71%” |
| Guselkumab | “$66,300” | “$44,400” | “$28,400” | “$41,500” | “37% to 57%” |
| Infliximab | “$38,100” | “$29,700” | “$18,800” | “$35,000” | “8% to 51%” |
| Ixekizumab | “$67,300” | “$37,700” | “$27,100” | “$39,700” | “41% to 60%” |
| Secukinumab | “$61,500” | “$38,200” | “$25,500” | “$39,400” | “36% to 59%” |
| Ustekinumab | “$58,200” | “$42,600” | “$25,200” | “$37,800” | “35% to 57%” |
| Risankizumab | Not available | Not available | “$27,300” | “$39,800” | Not available |
| Tildrakizumab | Not available | Not available | “$23,000” | “$36,800” | Not available |

Source: [ICER targeted immunomodulators for plaque psoriasis final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_Psoriasis_Update_Final_Evidence_Report_10042018.pdf)

<a id="topic-4.1-20"></a>

#### Eligible population and potential budget impact in the 2018 ICER assessment

> “The potential budget impact analysis included the entire candidate population for treatment, which included adults with moderate to severe plaque psoriasis who are taking a biologic agent for psoriasis for the first time.”
> “Psoriasis incidence in the United States has been estimated at 78.9 cases per 100,000 persons.”
> “Applying these proportions to the projected 2018-2022 U.S. adult population results in an average estimate of 29,342 incident cases of moderate-severe plaque psoriasis in the US per year, or approximately 146,710 incident cases over five years, assuming equal incidence rates for each of”
> “the five years in our analysis.”
> “For 2017-18, therefore, the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to total approximately $915 million per year for new drugs.”
> “At all prices except the price to reach the $50,000 per QALY threshold, the annual potential budgetary impact for the entire eligible population exceeded the ICER annual budget impact threshold of $915 million.”
> “The average potential budgetary impact when using the WAC was an additional per-patient cost of approximately $58,900 and approximately $37,200 using the assumed discount from WAC.”

Source: [ICER targeted immunomodulators for plaque psoriasis final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_Psoriasis_Update_Final_Evidence_Report_10042018.pdf)

<a id="topic-4.1-21"></a>

#### Base-case costs, QALYs, and cost per QALY in the 2016 ICER assessment

| Treatment | Cost | QALYs | Cost per QALY versus non-targeted therapy |
| --- | --- | --- | --- |
| Non-targeted therapy | “$88,086” | “5.531” | Not applicable |
| Adalimumab | “$208,881” | “6.649” | “$108,040” |
| Apremilast | “$161,741” | “6.353” | “$89,610” |
| Brodalumab | “$240,398” | “7.151” | “$94,030” |
| Etanercept | “$198,519” | “6.469” | “$117,769” |
| Infliximab | “$203,532” | “6.776” | “$92,715” |
| Ixekizumab | “$254,287” | “7.187” | “$100,389” |
| Secukinumab | “$221,704” | “7.018” | “$89,843” |
| Ustekinumab | “$269,843” | “6.930” | “$129,904” |

Source: [ICER targeted immunomodulators for plaque psoriasis final evidence report (2016)](https://icer.org/wp-content/uploads/2020/10/NE_CEPAC_Psoriasis_Evidence_Report_FINAL_012317.pdf)

> “Results for brodalumab are tentative, as pricing is not currently available”
> “Secukinumab is the most cost-effective agent versus non-targeted therapy.”
> “The incremental cost-effectiveness ratios versus etanercept ranged from approximately $42,000/QALY for secukinumab up to approximately $78,000 for ixekizumab.”
> “Analyses conducted using WAC (i.e., non-discounted) drug prices yielded cost-effectiveness ratios that ranged from $140,000 to $187,000 per QALY gained.”
> “First, all the targeted drugs had reasonably good value for money compared to non-targeted therapy, using our estimated, discounted drug costs.”

Source: [ICER targeted immunomodulators for plaque psoriasis final evidence report (2016)](https://icer.org/wp-content/uploads/2020/10/NE_CEPAC_Psoriasis_Evidence_Report_FINAL_012317.pdf)

<a id="topic-4.1-22"></a>

#### Value-based price benchmarks per unit in the 2016 ICER assessment

> “As shown in the table, with the exception of adalimumab, apremilast, and infliximab, all drugs would require discounts from current WAC prices to fall within ICER’s threshold value range of $100,000 to $150,000/QALY.”
> “Importantly, however, our estimates of net prices bring all the drugs of interest either within this threshold value range or generate cost-effectiveness ratios that are already <$100,000 per QALY gained.”

Source: [ICER targeted immunomodulators for plaque psoriasis final evidence report (2016)](https://icer.org/wp-content/uploads/2020/10/NE_CEPAC_Psoriasis_Evidence_Report_FINAL_012317.pdf)

| Drug and unit | Net price | WAC | Cost to achieve $100,000 per QALY | Cost to achieve $150,000 per QALY | Discount from WAC to reach threshold |
| --- | --- | --- | --- | --- | --- |
| Adalimumab 40 mg | “$1,433.98” | “$2,048.54” | “$1,311.40” | “$2,073.74” | “36% to +1%” |
| Apremilast 30 mg | “$34.48” | “$43.10” | “$42.94” | “$83.64” | “0.4% to +94%” |
| Brodalumab 210 mg | “$2,560.07” | “$4,266.79” | “$2,696.61” | “$3,840.28” | “10% to 37%” |
| Etanercept 50 mg | “$717.11” | “$1,024.44” | “$566.68” | “$989.98” | “3% to 45%” |
| Infliximab 100 mg | “$779.24” | “$1,113.27” | “$857.54” | “$1,395.18” | “23% to +25%” |
| Ixekizumab 80 mg | “$2,681.40” | “$4,469” | “$2,672.66” | “$3,795.25” | “15% to 40%” |
| Secukinumab 300 mg | “$2,438.74” | “$4,064.57” | “$2,680.73” | “$3,872” | “5% to 34%” |
| Ustekinumab 45 mg | “$7,514.19” | “$8,840.22” | “$5,886.50” | “$8,608.05” | “3% to 33%” |

Source: [ICER targeted immunomodulators for plaque psoriasis final evidence report (2016)](https://icer.org/wp-content/uploads/2020/10/NE_CEPAC_Psoriasis_Evidence_Report_FINAL_012317.pdf)

<a id="topic-4.1-23"></a>

#### Eligible population and potential budget impact of brodalumab and ixekizumab in the 2016 ICER assessment

> “The candidate population for treatment with these agents in our analysis is adults with moderate-to-severe plaque psoriasis who are taking a biologic agent for psoriasis for the first time.”
> “resulting in an estimate of approximately 36,750 incident cases of moderate-severe plaque psoriasis in the US per year, or approximately 183,750 incident cases over five years.”
> “For 2015-16, this threshold is calculated at $904 million per year for new drugs.”
> “Total potential budgetary impact of brodalumab over five years is approximately $1.2 billion, with an average budget impact per year of approximately $239.8 million.”
> “For ixekizumab, total potential budgetary impact over five years is approximately $1.3 billion, with an average budget impact per year of approximately $266 million.”

Source: [ICER targeted immunomodulators for plaque psoriasis final evidence report (2016)](https://icer.org/wp-content/uploads/2020/10/NE_CEPAC_Psoriasis_Evidence_Report_FINAL_012317.pdf)

<a id="topic-4.1-24"></a>

#### Ten-year cost-effectiveness of eight targeted therapies in a U.S. Markov model

> “We developed a Markov model to simulate patient outcomes as measured by quality-adjusted life-years (QALYs) and health care costs over a 10-year period.”
> “Wholesale acquisition drug costs were discounted by a class-specific, empirically derived rebate percentage off of 2016 costs.”
> “Costs of care without targeted treatment totaled $66,451, and costs of targeted treatment ranged from $137,080 (apremilast) to $255,422 (ustekinumab).”
> “Probabilistic sensitivity analysis results indicated that infliximab and apremilast are likely to be the most cost-effective initial treatments at willingness-to-pay thresholds around $100,000 per QALY, while IL-17 drugs are more likely to be cost-effective at thresholds approaching $150,000 per QALY.”

Source: [Hendrix et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10398188/)

| Treatment | Cost, $ | QALYs | ICER, $/QALY | ICER versus etanercept, $/QALY |
| --- | --- | --- | --- | --- |
| No treatment | “66,451” | “5.531” | Not applicable | Not applicable |
| Apremilast | “137,080” | “6.403” | “81,033 (vs. no treatment)” | Not applicable |
| Etanercept | “181,387” | “6.505” | “433,248 (vs. apremilast)” | Not applicable |
| Adalimumab | “194,180” | “6.681” | “72,703 (vs. etanercept)” | “72,703” |
| Infliximab | “176,695” | “6.804” | “Dominant” | “Dominant” |
| Ustekinumab | “255,422” | “6.959” | “Dominated” | “162,923” |
| Secukinumab | “208,727” | “7.045” | “132,913 (vs. infliximab)” | “50,661” |
| Brodalumab | “236,690” | “7.173” | “217,589 (vs. secukinumab)” | “82,766” |
| Ixekizumab | “243,938” | “7.208” | “208,872 (vs. brodalumab)” | “88,991” |

Source: [Hendrix et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10398188/)

<a id="topic-4.1-25"></a>

#### Cost-effectiveness of tildrakizumab and other first-line targeted therapies over 10 years

> “Over 10 years, the incremental cost per QALY gained compared with a mix of topical therapies, phototherapies, and other oral systemic therapies was lowest for brodalumab, infliximab, apremilast, and tildrakizumab, followed by secukinumab, ixekizumab, guselkumab, adalimumab, ustekinumab, and etanercept.”
> “The position of tildrakizumab relative to the other treatments remained the same across multiple scenarios.”

Source: [Jia et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/32602762/)

> “A 10-year cost-effectiveness model was developed to compare the incremental cost per extra month with a Psoriasis Area and Severity Index (PASI) 75 response.”
> “The incremental cost per extra month a patient had a PASI 75 response was lowest for brodalumab ($3,685), infliximab ($4,102), apremilast ($4,770), and tildrakizumab ($5,150), followed by risankizumab ($5,319), secukinumab ($5,675), guselkumab ($5,784), ixekizumab ($5,900), adalimumab ($5,943), ustekinumab ($6,131), etanercept ($6,618), and certolizumab pegol ($13,476).”

Source: [Wu et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32233828/)

<a id="topic-4.1-26"></a>

#### Costs and quality-adjusted life-years of biologics, phototherapy, and step therapy in a simulation model

> “Simulation modeling study in patients with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index [PASI] ≥12) using published estimates of efficacy, costs, and mappings between PASI score and quality-adjusted life-years (QALYs) from 2013 through 2025.”
> “Mean (SD) QALY gains were 0.24 (0.08) for biologics, 0.18 (0.09) for phototherapy, and 0.23 (0.06) for step therapy.”
> “Mean (SD) annual total costs were $84 034 (0) for biologics, $14 760 (0) for office phototherapy, and $6222 (0) for home phototherapy.”
> “From the payer perspective, mean (SD) net willingness to pay was highest for home phototherapy ($11 694 [$9421]) and lowest for biologics (-$59 926 [$7916]).”
> “Among biologics, payers preferred adalimumab, whereas patients preferred bimekizumab.”

Source: [Kong and Buzney (2026)](https://pubmed.ncbi.nlm.nih.gov/41739454/)

<a id="topic-4.1-27"></a>

#### U.S. net prices of psoriasis biologics and price reductions under an efficiency frontier

> “In this economic evaluation, US net prices of 13 biologic therapies for psoriasis ranged from $1664 to $79 277 per year, and clinical efficacy measured by Psoriasis Area Severity Index 90 scores ranged from 17.9% to 71.6%.”
> “The median (IQR) net annual treatment cost was higher in the US ($34 965 [$20 493-$48 942]) than prerebate costs in Australia ($9179 [$6691-$12 688]), Canada ($15 556 [$13 017-$16 112]), France ($9478 [$6637-$11 678]), and Germany ($13 829 [$13 231-$15 837]).”
> “US prices for psoriasis biologics would need to be reduced by a median (IQR) of 71% (31%-95%) to align with those estimated using the EF; the same approach would yield smaller price reductions in Canada (41% [6%-57%]), Australia (36% [0%-65%]), France (19% [0%-67%]), and Germany (11% [8%-26%]).”

Source: [Egilman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10882509/)

| Drug | PASI 90 response rate, % | Estimated net price per year, $ |
| --- | --- | --- |
| Etanercept | “17.9” | “46 967” |
| Adalimumab | “43.7” | “54 867” |
| Ustekinumab | “43.9” | “25 182” |
| Certolizumab pegol | “45.6” | “31 910” |
| Infliximab (Remicade) | “57.4” | “6426” |
| Secukinumab | “61.4” | “36 926” |
| Guselkumab | “67.3” | “41 852” |
| Brodalumab | “70.6” | “58 041” |
| Ixekizumab | “70.8” | “33 004” |
| Risankizumab | “71.6” | “79 277” |

Source: [Egilman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10882509/)

<a id="topic-4.1-28"></a>

#### Cost per response of deucravacitinib and apremilast from a U.S. payer perspective

> “A CPR model using pharmacy and administration costs was developed from a US payer perspective.”
> “The CPR for deucravacitinib versus apremilast was lower at 16 weeks (difference: -$3796 [95% confidence interval (CI): -$6140 to -$1659]) and 24 weeks (difference: -$12,784 [95% CI: -$16,674 to -$9369]).”
> “At 52 weeks, the cost per cumulative benefit was lower for patients who initiated deucravacitinib, regardless of initial treatment period duration (16 or 24 weeks).”

Source: [Park et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38914425/)

<a id="topic-4.1-29"></a>

#### Annual cost per PASI 75, PASI 90, and PASI 100 response for five biologics

> “Total annual costs to a health plan per patient with adalimumab, brodalumab, ixekizumab, secukinumab and ustekinumab were estimated at $51,246, $38,538, $65,484, $57,510 and $57,013.”
> “Mean annual treatment costs per PASI 75, 90 and 100 were the lowest for brodalumab, with the annual cost per PASI 75 for brodalumab, adalimumab, ixekizumab, secukinumab and ustekinumab estimated at $48,782, $82,655, $77,957, $75,671 and $87,243, per PASI 90 at $51,383, $119,178, $94,904, $108,509 and $130,615, and per PASI 100 at $87,585, $284,702, $176,983, $205,393, and $366,645.”

Source: [Wu et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29658383/)

<a id="topic-4.1-30"></a>

#### Cost per PASI 90 response for guselkumab in head-to-head trials with adalimumab and secukinumab

> “The CPR for PASI 90 in the induction year for guselkumab was $113,861 vs $151,226 for adalimumab.”
> “The NNT for a PASI 90 response was 1.3 for guselkumab and 2.1 for adalimumab; CPRs and NNT were also lower for guselkumab than for adalimumab for PASI 75 and PASI 100 for both induction and maintenance years.”

Source: [Teeple and Muser (2019)](https://pubmed.ncbi.nlm.nih.gov/31199173/)

> “The CPR for PASI 90 response at 48 weeks was $89,960 for guselkumab versus $110,977 for secukinumab, and for the maintenance year it was $77,109 for guselkumab versus $88,781 for secukinumab.”
> “The NNT for a PASI 90 response was 1.18 for guselkumab and 1.43 for secukinumab.”

Source: [Teeple and Fitzgerald (2022)](https://pubmed.ncbi.nlm.nih.gov/32479140/)

<a id="topic-4.1-31"></a>

#### Cost per cumulative clinical benefit of seven biologics over 16 weeks

> “Cost per cumulative benefit was estimated by multiplying number of doses (per FDA label) by nationally representative discounted wholesale acquisition costs (WACs) for 16 weeks of treatment divided by %Max_AUCW16.”
> “In the primary analysis, guselkumab had the lowest cost per cumulative benefit (95% credible interval [CrI]; $99,742 [$89,941-$111,653]), followed by ixekizumab ($108,906 [$95,928-$126,093]) and adalimumab ($111,233 [$97,549-$129,022]) for PASI 90, and ixekizumab had the lowest cost per cumulative benefit ($230,884 [$191,611-$291,115]), followed by secukinumab ($238,945 [$204,029-$288,072]) and risankizumab ($279,968 [$250,683-$316,872]) for PASI 100 responses.”
> “Certolizumab pegol had the highest cost per cumulative benefit ($412,463 [$349,856-$499,199]) for PASI 90 response, and ustekinumab had the highest cost per cumulative benefit ($488,654 [$411,859-$601,642]) for PASI 100 response (Figure 2).”

Source: [Blauvelt et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391184/)

<a id="topic-4.1-32"></a>

#### Monthly cost per PASI 75 response of biologics and narrowband ultraviolet B phototherapy

> “Phototherapy costs were estimated with Medicare fee schedules for phototherapy-related current procedural terminology code (CPT), and biologic costs were estimated with wholesale acquisition cost (WAC).”
> “The psoriasis analysis found NB-UVB to be the most cost-effective therapy, with an adjusted monthly cost of $1714.00 per PASI 75.”
> “Infliximab was the least expensive biologic, with an adjusted monthly cost of $2076.00 to $2502.00 per PASI 75.”

Source: [McCoy et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37066447/)

<a id="topic-4.1-33"></a>

#### Budget impact of adding tildrakizumab to a U.S. health plan of 1 million members

> “The number of patients eligible for treatment was calculated from the US prevalence estimates for moderate-to-severe plaque psoriasis [1, 2, 4].”
> “Among all patients with moderate-to-severe plaque psoriasis, 20% were assumed to be treated with biologic treatments or apremilast [10], of whom 36% were estimated to be new to treatment due to incident psoriasis or switching between treatments [6, 7].”

Source: [Carrico et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7688845/)

| Population characteristic | Base case |
| --- | --- |
| Number of members in health plan | “1,000,000” |
| Prevalence of psoriasis | “3.2%” |
| Proportion with plaque psoriasis | “90.0%” |
| Proportion with moderate-to-severe psoriasis | “18.2%” |
| Proportion treated with a biologic or apremilast | “20.0%” |
| New biologic or apremilast treatment users (require induction dosing) | “35.6%” |

Source: [Carrico et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7688845/)

> “Within a health plan of 1 million members with an estimated 1048 patients receiving biologics or apremilast for psoriasis, the total annual health plan cost after introducing tildrakizumab decreased by $5585, $137,025, $205,538, $274,051, and $342,563 in years 1–5, respectively, resulting in a cumulative reduction of $964,763 over 5 years.”
> “The incremental per member per month (PMPM) cost reductions were negligible in year 1, $0.01 in year 2, $0.02 in years 3–4, and $0.03 in year 5.”
> “Annual acquisition costs for biologic treatments and apremilast were based on wholesale acquisition costs (WACs) from May 2019 [11] and recommended dosing regimens from the corresponding prescribing information (Table 1).”

Source: [Carrico et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7688845/)

<a id="topic-4.1-34"></a>

#### Budget impact of brodalumab on U.S. commercial health plans of 2 million members

> “In a hypothetical commercial health plan covering two million members, 7,038 moderate-to-severe psoriasis patients were estimated to be eligible for treatment with brodalumab.”
> “When no brodalumab is used, the total annual pharmacy budget for the biologics used among these patients was estimated at $414,362,647.”
> “Among scenarios where the proportions of brodalumab usage were 3%, 8%, 16%, and 30%, the total annual pharmacy cost was estimated to be reduced by $3,698,129, $9,861,677, $19,723,355, and $36,981,290, respectively.”

Source: [Feldman et al. (2018a)](https://pubmed.ncbi.nlm.nih.gov/29357713/)

<a id="topic-4.1-35"></a>

#### Economic analyses that include envudeucitinib

No evidence found.

<a id="topic-4.1-36"></a>

#### Market size and treatment penetration stated by Alumis

> “Large marketplace with modest treatment penetration with future growth expected to be driven primarily by next-generation orals”
> “Icotyde’s uptake is largely additive, with launch expanding the market rather than simply redistributing share within it”
> “Historical market share trends confirm PsO is a multi-winner market, where several brands can succeed concurrently rather than one dominating at others' expense”
> “Envudeucitinib’s profile may address a broader set of needs, tapping into large underpenetrated market opportunity.”
> “84% of patients and 73% of dermatologists believe there is a need for better psoriasis therapies”

Source: [Alumis corporate presentation, November 2026 (2026)](https://investors.alumis.com/static-files/08630d4b-a14b-447f-a46d-c963632af8a4)

<a id="topic-4.1-37"></a>

#### Basis of Alumis market estimates and pricing constraints stated in its annual report

> “The precise incidence and prevalence for all the conditions we aim to address with our product candidates are unknown.”
> “Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates.”
> “These estimates have been derived from a variety of sources, including sales of our competitors, scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect in general, or as to their applicability to our company.”
> “Even if we show improved efficacy, safety or improved convenience of administration with envu, A-005 or any of our future product candidates, if approved, pricing of competitive products may limit the amount we will be able to charge for our product”
> “candidates, if approved.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

No evidence found.

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

No evidence found.

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

No evidence found.

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

No evidence found.

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

No evidence found.

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

No evidence found.

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

No evidence found.

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

No evidence found.

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
